Company news: Pfizer and Bristol-Myers Squibb
The FDA granted priority review status to Eliquis (apixaban), the novel oral anticoagulant being developed by Pfizer and Bristol-Myers Squibb.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.